TRV GP Iv, LLC

In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 7, 2026), TRV GP Iv, LLC reported 2 stock positions worth $266.9 million. Its top holding was Maze Therapeutics (MAZE) at 50.0% of the portfolio, followed by Tango Therapeutics (TNGX, 50.0%). Compared with Q4 2025, it reduced 1. The biggest sale was Tango Therapeutics (TNGX, shares −19%).

Most Recent 13F
Q2 2026
Location
Boston, MA
CIK
0001688325
Portfolio Value
$266.9M (Q1 2026)
SEC Filing
0001193125-26-212011 ↗ filed May 7, 2026

Holdings Value

0$100.0M$200.0M$300.0M Q1 2024: $206.4M Q1 2024 Q2 2024: $202.2M Q2 2024 Q3 2024: $162.1M Q3 2024 Q4 2024: $80.2M Q4 2024 Q1 2025: $92.9M Q1 2025 Q2 2025: $163.3M Q2 2025 Q3 2025: $274.0M Q3 2025 Q4 2025: $255.1M Q4 2025 Q1 2026: $266.9M $266.9M Q1 2026 Q2 2026: $253.7M Q2 2026

Holdings 2 stocks · $266.9M
MAZE Maze Therapeutics Inc. 50.04% 4,473,958 $133.5M No change
TNGX Tango Therapeutics Inc. 49.96% 6,374,574 $133.4M Reduce -19.1%

Portfolio Sells Q4 2025 → Q1 2026
TNGX Tango Therapeutics Inc. Reduce -19.1% 49.96% +22.62

Portfolio Buys Q4 2025 → Q1 2026
None this quarter.

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 2$253.7MMAZE, TNGX
Q1 2026 2$266.9MMAZE, TNGX
Q4 2025 2$255.1MMAZE, TNGX
Q3 2025 2$274.0MMAZE, TNGX
Q2 2025 3$163.3MTNGX, MAZE, PLRX
Q1 2025 3$92.9MMAZE, TNGX, PLRX
Q4 2024 2$80.2MTNGX, PLRX
Q3 2024 3$162.1MTNGX, PLRX, FULC
Q2 2024 3$202.2MTNGX, PLRX, FULC
Q1 2024 3$206.4MTNGX, PLRX, FULC